URGN
UroGen Pharma Ltd

2,286
Mkt Cap
$857.78M
Volume
975,333.00
52W High
$30.00
52W Low
$3.42
PE Ratio
-5.49
URGN Fundamentals
Price
$17.62
Prev Close
$18.59
Open
$18.63
50D MA
$20.20
Beta
1.07
Avg. Volume
706,097.96
EPS (Annual)
-$3.19
P/B
-8.08
Rev/Employee
$377,278.35
$1,135.16
Loading...
Loading...
News
all
press releases
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN
JPMorgan Chase & Co. raised its stake in Urogen Pharma (NASDAQ:URGN - Free Report) by 36.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·17d ago
News Placeholder
More News
News Placeholder
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat
Urogen Pharma (NASDAQ:URGN) Shares Gap Up on Better-Than-Expected Earnings...
MarketBeat·19d ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5% - Should You Sell?
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5% - Time to Sell...
MarketBeat·20d ago
News Placeholder
Urogen Pharma Q4 Earnings Call Highlights
Urogen Pharma (NASDAQ:URGN) executives used the company's fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product...
MarketBeat·20d ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Monday...
MarketBeat·20d ago
News Placeholder
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS
Urogen Pharma (NASDAQ:URGN - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by...
MarketBeat·20d ago
News Placeholder
UroGen Pharma: Q4 Earnings Insights
read more...
Benzinga·20d ago
News Placeholder
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Monday
Urogen Pharma (NASDAQ:URGN) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·21d ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by Analysts
Urogen Pharma (NASDAQ:URGN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat Ratings...
MarketBeat·22d ago
<
1
2
...
>

Latest URGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.